- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Unmet Needs and the Increased Use of Targeted Therapy in CLL
Steven Peskin, MD, MBA, FACP: The question is, how is managed care shifting from chemotherapy to targeted therapy [in] chronic lymphocytic leukemia (CLL)? The use of, and application of, targeted therapies, precision medicine, and immunotherapies as being more effective with better safety profiles, side effect profiles, [and] tolerability profiles, is very, very exciting.
We are certainly very positive about that—sanguine about that. [We are] working with our clinical partners to help them through analytics (predictive analytics), harmonization of our data, and tools with our clinical organizations. So, it is to my way of thinking [that this] really represents the future of cancer care.
[With regard to] CLL unmet needs (in treatment), would we like to have a cure? Absolutely. So, that would be an unmet need. If we were able to have our wish list, and we were able to develop a cancer vaccine—something that was truly blocking or arresting the pathway that led to the genetic defect or protein expression, gene expression (what’s called epigenetics)—then that would be the unmet need. That’s certainly what major scientists are working on, and I’m sure there will be Nobel Prizes conferred over the next generation.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
